{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007587","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2026-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.638598+00:00","generated_at":"2026-05-16T01:27:46.352442+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BriaCell transfers exclusive sCD80 license to BriaPro; receives 23.97M shares, increases stake to 78%","bullets":["BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.","BriaCell provides up to $3M credit facility to BriaPro for R&D; each drawdown subject to BriaCell approval.","Transaction expected to close March 12, 2026, subject to disinterested shareholder approval and independent valuation.","License originally from University of Maryland Baltimore County; sCD80 showed anti-tumor activity in animal models.","BriaPro stock valued at approx. C$1.18M aggregate; BriaPro to pay 2% royalties to UMBC upon commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007587","json":"https://secwatch.observer/filing/0001493152-26-007587.json","markdown":"https://secwatch.observer/filing/0001493152-26-007587.md","text":"https://secwatch.observer/filing/0001493152-26-007587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226007587/0001493152-26-007587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226007587/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:27:46.352442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}